|
|
Recent Articles
-
Republic Services Remains a Cash Cow
Feb 19, 2025
-
Image Source: Republic Services.
For the full year, Republic’s cash provided by operating activities was $3.94 billion, up 8.8% from last year. Adjusted free cash flow was $2.18 billion, an increase of 10% versus the prior year. The company returned $1.18 billion in cash to shareholders during 2024, consisting of $490 million of share repurchases and $687 million of dividends paid. Looking to 2025, Republic expects revenue in the range of $16.85-$16.95 billion and adjusted EBITDA in the range of $5.275-$5.325 billion. Adjusted diluted earnings per share is targeted in the range of $6.82-$6.90 for the year, while adjusted free cash flow is expected in the range of $2.32-$2.36 billion. We continue to like Republic Services as an idea in the newsletter portfolios.
-
Dividend Increases/Decreases for the Week of February 14
Feb 14, 2025
-
Let's take a look at firms raising/lowering their dividends this week.
-
Cisco Ups Fiscal 2025 Guidance Again
Feb 13, 2025
-
Image Source: Cisco.
Looking to fiscal third quarter guidance, Cisco's revenue is expected to be between $13.9-$14.1 billion, and non-GAAP earnings per share to be between $0.90-$0.92. For all of fiscal 2025, management expects revenue in the range of $56-$56.5 billion (was $55.3-$56.3 billion) and non-GAAP earnings per share in the range of $3.68-$3.74 (was $3.60-$3.66 per share). We continue to like Cisco as a holding in both the Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio. The high end of our fair value estimate range stands at $73 per share.
-
Vertex Pharma Is One of Our Favorite Biotechs
Feb 11, 2025
-
Image: Vertex Pharma has performed quite well since the beginning of 2023.
Looking to 2025, Vertex expects total revenue of $11.75-$12 billion, which includes expectations for continued growth in its cystic fibrosis portfolio, “including the U.S. launch of ALYFTREK, as well as continued uptake of CASGEVY in multiple regions; and early contributions from the launch of JOURNAVX." Cash and total marketable securities as of the end of last year were $11.2 billion, compared to $13.7 billion at the end of 2023 due to the cash consideration paid to acquire Alpine and share buybacks. Vertex had no traditional debt. We continue to like Vertex Pharma as a holding in the Best Ideas Newsletter portfolio.
|
